Company · CIK 0001601830 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
RECURSION PHARMACEUTICALS, INC. · RXRX
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 FForm 4 → | Sep 16, 5:52 pm EDT | Ben R TaylorChief Financial Officer | 5,396 | $3.41 | $18,400 | 1,071,462 | — | |
| Sep 8, 2026 SForm 4 → | Sep 10, 5:55 pm EDT | Najat KhanCEO and President, Director | 22,408 | $3.52 | $78,822 | 2,072,890 | −1.07% | 10b5-1 |
| Sep 1, 2026 SForm 4 → | Sep 2, 6:01 pm EDT | Blake BorgesonDirector | 30,000 | $3.34 | $100,200 | 6,158,287 | −0.48% | 10b5-1 |
| Aug 17, 2026 FForm 4 → | Aug 18, 5:44 pm EDT | Najat KhanCEO and President, Director | 80,498 | $3.16 | $254,374 | 2,095,298 | — | |
| Aug 17, 2026 FForm 4 → | Aug 18, 5:44 pm EDT | David HallettChief Scientific Officer | 26,657 | $3.16 | $84,236 | 1,043,837 | — | |
| Aug 17, 2026 FForm 4 → | Aug 18, 5:44 pm EDT | Ben R TaylorChief Financial Officer | 25,018 | $3.16 | $79,057 | 1,076,858 | — | |
| Aug 4, 2026 SForm 4 → | Aug 6, 5:09 pm EDT | Blake BorgesonDirector | 30,000 | $3.25 | $97,500 | 6,188,287 | −0.48% | 10b5-1 |
| Jul 7, 2026 SForm 4 → | Jul 9, 6:04 pm EDT | Blake BorgesonDirector | 40,000 | $3.96 | $158,500 | 6,218,287 | −0.64% | 10b5-1 |
| Jul 1, 2026 AForm 4 → | Jul 2, 5:15 pm EDT | Zavain DarDirector | 5,109 | — | — | 240,764 | — | |
| Jul 1, 2026 AForm 4 → | Jul 2, 5:15 pm EDT | Dean Y LiDirector | 3,747 | — | — | 1,473,329 | — |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.